Celldex Therapeutics: More Promising Results in Treating Chronic Spontaneous Urticaria Refractory to Antihistamines

Celldex Therapeutics Interim Trial Data for Barzolvolimab
Interim data from Celldex Therapeutics (CLDX) Phase 1b clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines demonstrate meaningful symptom improvements. The results showed that multiple doses of barzolvolimab resulted in dose-dependent decreases in itch and hives, as measured through the urticaria activity score over . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.